Expand NNVC Menu
NNVC MENU

NNVC Latest Press Releases

-- July 24, 2026 --

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering ACCESS Newswire 8:00 AM

-- July 22, 2026 --

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola ACCESS Newswire 8:30 AM

-- July 13, 2026 --

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo ACCESS Newswire 9:27 AM

-- July 8, 2026 --

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily ACCESS Newswire 8:30 AM

-- July 6, 2026 --

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo ACCESS Newswire 8:30 AM

-- June 29, 2026 --

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher ACCESS Newswire 8:30 AM

-- June 22, 2026 --

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo ACCESS Newswire 9:30 AM

-- June 15, 2026 --

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo ACCESS Newswire 8:30 AM

-- June 8, 2026 --

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies ACCESS Newswire 8:30 AM

-- May 26, 2026 --

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides ACCESS Newswire 8:31 AM

-- May 18, 2026 --

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering ACCESS Newswire 11:55 PM
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides ACCESS Newswire 8:30 AM

-- May 15, 2026 --

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering ACCESS Newswire 8:35 AM
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II ACCESS Newswire 8:00 AM

-- May 11, 2026 --

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides ACCESS Newswire 8:30 AM

-- May 4, 2026 --

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA ACCESS Newswire 8:30 AM

-- April 21, 2026 --

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides ACCESS Newswire 8:30 AM

-- April 7, 2026 --

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides ACCESS Newswire 8:30 AM

-- April 1, 2026 --

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides ACCESS Newswire 8:30 AM

-- March 11, 2026 --

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete ACCESS Newswire 8:30 AM
Market Data Delayed 15 Minutes